The #Hemagglutinin Stem-Binding #mAb VIS410 Controls #Influenza #Virus–Induced #ARDS (Antimicrob Agents Chemother., abstract)

[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus–Induced Acute Respiratory Distress Syndrome [      ]

Tatiana Baranovich a, Jeremy C. Jones a, Marion Russier a, Peter Vogel b, Kristy J. Szretter c, Susan E. Sloan c#, Patrick Seiler a, Jose M. Trevejo c, Richard J. Webby a and Elena A. Govorkova a#

Author Affiliations: Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USAa Department of Veterinary Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USAb Visterra, Inc., Cambridge, Massachusetts, USAc



Most cases of severe influenza are associated with pulmonary complications, such as acute respiratory distress syndrome (ARDS), and no antiviral drugs of proven value for treating such complications are currently available. The use of monoclonal antibodies targeting the stem of the influenza virus surface hemagglutinin (HA), is a rapidly developing strategy for controlling viruses of multiple HA subtypes. However, the mechanisms of action of these antibodies are not fully understood, and their ability to mitigate severe complications of influenza has been poorly studied. We evaluated the effect of treatment with VIS410, a human monoclonal antibody targeting the HA stem region, on the development of ARDS in BALB/c mice after infection with influenza A(H7N9) viruses. Prophylactic administration of VIS410 resulted in complete protection of mice against lethal A(H7N9) virus challenge. A single therapeutic dose of VIS410 given 24 h after virus inoculation resulted in dose-dependent protection of up to 100% of mice inoculated with neuraminidase inhibitor–susceptible or –resistant A(H7N9) viruses. Compared to the outcomes in mock-treated controls, a single administration of VIS410 improved viral clearance from the lungs; reduced virus spread in lungs in a dose-dependent manner, resulting in a lower lung injury score; reduced the extent of the alteration in lung vascular permeability and protein accumulation in bronchoalveolar lavage fluid; and improved lung physiologic function. Thus, antibodies targeting the HA stem can reduce the severity of ARDS and show promise as agents for controlling pulmonary complications in influenza.



#Correspondence should be addressed to: Elena A. Govorkova (Primary Corresponding Author), Department of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; FAX: (901)-595-8559, Phone: (901)-595-2243, E-mail:

#Susan Sloan, Visterra, Inc., One Kendall Square, Suite B3301 Building 300, Cambridge, MA 02139, USA; FAX: (617)-498-1073. Phone: (617)-498-1070 x313, E-mail:

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Keywords: Research; Abstracts; Influenza; Monoclonal Antibodies; ARDS.


Published by

Giuseppe Michieli

I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum ( in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.